Stereotactic versus hippocampal avoidance whole-brain radiotherapy combined with immune checkpoint inhibitors for multiple brain metastases in non-small cell lung cancer: a multi-center retrospective study - Scorecard - MDSpire
Advertisement
Comparison of Stereotactic Radiotherapy and Hippocampal Avoidance Whole-Brain Radiotherapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases: A Multi-Center Retrospective Analysis
Clinical Scorecard: Comparison of Stereotactic Radiotherapy and Hippocampal Avoidance Whole-Brain Radiotherapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases: A Multi-Center Retrospective Analysis
At a Glance
Category
Detail
Condition
Non-Small Cell Lung Cancer with Multiple Brain Metastases
Key Mechanisms
Stereotactic Radiotherapy (SRT) and Hippocampal Avoidance Whole-Brain Radiotherapy (HA-WBRT) combined with Immune Checkpoint Inhibitors (ICIs)
Target Population
Patients with Non-Small Cell Lung Cancer and more than four brain metastases
Care Setting
Retrospective analysis in multi-center clinical practice
Key Highlights
SRT+ICIs showed significantly longer median overall survival (21.4 months) compared to HA-WBRT+ICIs (15.5 months; P<0.001).
SRT+ICIs also demonstrated improved median intracranial progression-free survival (10.5 months vs. 8.1 months; P<0.001).
No grade > 3 adverse events were reported in either treatment cohort.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of Non-Small Cell Lung Cancer with MRI showing multiple brain metastases (>4 lesions).
Management
Consider SRT+ICIs as a treatment option for improved overall survival and intracranial progression-free survival.
Monitoring & Follow-up
Monitor overall survival and intracranial progression-free survival as primary endpoints.
Risks
Assess for potential adverse events, although no grade > 3 AEs were found in this study.
Patient & Prescribing Data
NSCLC patients with multiple brain metastases treated with RT and ICIs.
SRT combined with ICIs may enhance treatment efficacy without increasing adverse events.
Clinical Best Practices
Utilize propensity score matching to balance baseline characteristics in treatment comparisons.
Incorporate multidisciplinary review for target volume delineation in SRT planning.
